Loading
DNA Repair Mechanisms · Journal article
Frontiers in Pharmacology · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing that chromatin adaptation and histone remodeling—particularly via NASP, INO80, and FACT pathways—may underlie PARP inhibitor resistance in cancer stem cells. The authors synthesize emerging mechanistic evidence and identify potential therapeutic targets, but explicitly state that further experimental validation is required and present no new clinical or experimental data.
Journal article. Conceptual: homologous recombination-deficient tumors and cancer stem cell populations; no specific clinical population studied..
PARP inhibition drives acute depletion of H3-H4 histones, creating cellular reliance on efficient histone recycling. NASP histone chaperone sequesters evicted histones from degradation and promotes chromatin recovery. Cancer stem cells rely on dynamic chromatin plasticity to switch phenotypic states and resist therapy.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies potential mechanisms and therapeutic targets to combat PARP inhibitor resistance, but clinicians should recognize these are proposed hypotheses requiring experimental validation. No immediate practice-changing recommendations are presented.
A narrative review proposing mechanistic hypotheses about chromatin adaptation in PARP inhibitor resistance, without new experimental data or clinical evidence to test these mechanisms.
This review identifies potential mechanisms and therapeutic targets to combat PARP inhibitor resistance, but clinicians should recognize these are proposed hypotheses requiring experimental validation. No immediate practice-changing recommendations are presented.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of homologous recombination (HR)-deficient tumors. Nevertheless, their clinical utility is often compromised by the emergence of resistance. Although genetic restoration of HR is a well-established resistance mechanism, emerging evidence suggests that epigenetic and chromatin responses are also central determinants of cell survival under PARPi-induced stress. Indeed, PARP inhibition drives the acute depletion of H3-H4 histones, thereby creating a cellular reliance on efficient histone recycling to ensure genome integrity. The histone chaperone Nuclear Autoantigenic Sperm Protein (NASP) has recently been implicated as a critical regulator in this process by sequestering evicted histones from degradation and promoting chromatin recovery. This NASP-dependent histone turnover may be particularly relevant to cancer stem cell (CSC) biology, as CSCs rely on dynamic chromatin plasticity to switch between phenotypic states and resist therapy. In this review, we focus on the intersection of histone dynamics and CSC survival, with particular emphasis on the ATP-dependent chromatin remodeler inositol-requiring mutant 80 (INO80), the NASP histone maintenance axis, and histone chaperones such as Facilitates Chromatin Transcription (FACT) as potential therapeutic targets. Targeting these chromatin maintenance pathways may provide new opportunities to overcome PARPi resistance and limit the persistence of resistant CSC subpopulations, although further experimental validation is required.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.